COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,306 Articles (22,772 medRxiv, 8,534 bioRxiv)

Most recent first Previous |  Page 1911: Articles 19101-19110  | Next

Microsecond simulation unravel the structural dynamics of SARS-CoV-2 Spike-C-terminal cytoplasmic tail (residues 1242-1273)
Kumar, P., Bhardwaj, T., Giri, R., Garg, N.
10.1101/2021.01.11.426227 — Posted: 2021-01-11
Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment
Cheng, M. H., Krieger, J. M., Kaynak, B., Arditi, M. A., Bahar, I.
10.1101/2021.01.10.426143 — Posted: 2021-01-11
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques
van Doremalen, N., Purushotham, J., Schulz, J., Holbrook, M., Bushmaker, T., Carmody, A., Port, J., Yinda, K. C., Okumura, A., Saturday, G., Amanat, F., Krammer, F., Hanley, P., Smith, B., Lovaglio, J., Anzick, S., Barbian, K., Martens, C., Gilbert, S. C., Lambe, T., Munster, V.
10.1101/2021.01.09.426058 — Posted: 2021-01-11
COVID-19 Severity Is Associated with Differential Antibody Fc-mediated Innate Immune Functions
Adeniji, O. S., Giron, L. B., Zilberstein, N. F., Shaikh, M. W., Balk, R. A., Moy, J. N., Forsyth, C. B., Keshavarzian, A., Landay, A. L., Abdel-Mohsen, M.
10.1101/2021.01.11.426209 — Posted: 2021-01-11
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination
Tscherne, A., Schwarz, J. H., Rohde, C., Kupke, A., Kalodimou, G., Limpinsel, L., Okba, N. M. A., Bosnjak, B., Sandrock, I., Halwe, S., Sauerhering, L., Printz, K., Nan, L., Duell, E., Jany, S., Freudenstein, A., Schmidt, J., Werner, A., Gellhorn, M., Kluever, M., Guggemos, W., Seilmaier, M., Wendtner, C., Foerster, R., Haagmans, B., Becker, S., Sutter, G., Volz, A.
10.1101/2021.01.09.426032 — Posted: 2021-01-11
Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
Rapp, M., Guo, Y., Reddem, E. R., Liu, L., Wang, P., Yu, J., Cerutti, G., Bimela, J., Bahna, F., Mannepalli, S., Zhang, B., Kwong, P. D., Ho, D. D., Shapiro, L., Sheng, Z.
10.1101/2021.01.11.426218 — Posted: 2021-01-11
Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2 in Preclinical Animal Models
Park, J.-G., Oladunni, F. S., Rohaim, M. A., Whittingham-Dowd, J., Tollitt, J., Assas, B. M., Alhazmi, W., Almilaibary, A., Iqbal, M., Chang, P., Escalona, R., Shivanna, V., Torrelles, J. B., Worthington, J. J., Jackson-Jones, L. H., Martinez-Sobrido, L., Munir, M.
10.1101/2021.01.08.425974 — Posted: 2021-01-11
Molecular Dynamics Analysis of a Flexible Loop at the Binding Interface of the SARS-CoV-2 Spike Protein Receptor-Binding Domain
Williams, J. K., Wang, B., Sam, A., Hoop, C. L., Case, D. A., Baum, J.
10.1101/2021.01.08.425965 — Posted: 2021-01-11
Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite
Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., Huang, Y., Katsamba, P. S., Lihong, L., Nair, M. S., Rawi, R., Olia, A. S., Wang, P., Chuang, G.-Y., Ho, D. D., Sheng, Z., Kwong, P. D., Shapiro, L.
10.1101/2021.01.10.426120 — Posted: 2021-01-11
Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2 and heparan sulfate
Prieto-Fernandez, E., Egia-Mendikute, L., Vila-Vecilla, L., Lee, S. Y., Bosch, A., Barreira-Manrique, A., Garcia del Rio, A., Antonana-Vildosola, A., Jimenez-Lasheras, B., Palazon, A.
10.1101/2021.01.09.426021 — Posted: 2021-01-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).